Analyst Coverage
Audio Archives
Calendar of Events
Corporate Governance
Directions
E-mail Alerts
Earnings Estimates
FAQ
Financial Reports
Fundamentals
Information Request
Investor Kit
Media
Proxy Materials
Press Releases
Product Pipeline
SEC Filings
Services & Contacts
Stock Information
Investor Tool Kit
E-mail PageE-mail Page
RSS FeedsRSS Feeds
E-mail AlertsE-mail Alerts
IR ContactsIR Contacts
Financial Tear SheetFinancial Tear Sheet

Investor Relations

Stock Quote
CELG (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$54.77
Change (%) Stock is Down 0.39 (0.71%)
Volume2,335,564
Data as of 02/08/10 4:48 p.m. ET
Minimum 20 minute delay
Refresh quote
Corporate Profile

Celgene Corporation and its subsidiaries (collectively “we” or “our”) is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. Our primary commercial stage products include REVLIMID®, THALOMID® and VIDAZA® . REVLIMID® is an oral immunomodulatory drug marketed in the U.S. and Europe for patients with multiple myeloma who have receiv... More >>

Recent News
DateTitle 
01/28/10Celgene Reports Record Fourth Quarter and Full Year 2009 Product Sales and Operating Income
Record Fourth Quarter and Full Year Results Driven By Gains in Global Market Share, Duration of Therapy and Reimbursement Approvals REVLIMID(R) Fourth Quarter Global Net Product Sales Increased 35% Y/Y and 11% Q/Q VIDAZA(R) Fourth Quarter Global Net Product Sales Increased 68% Y/Y and 13% Q/Q Full Year Non-GAAP Diluted Earnings Per Share Increased 33% Y/Y SUMMIT, N.J., Jan 28, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG): 2009 Fourth Quarter Financial Results Year-Over-Y... 
Printer Friendly Version
01/19/10Celgene Corporation to Announce Fourth Quarter and Full-Year 2009 Results on January 28, 2010
SUMMIT, N.J., Jan 19, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, January 28, 2010 at 9 a.m. ET to discuss the company's fourth quarter and full-year 2009 financial and operational results. The webcast will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene Corporation, headquartered in Summit, New Jersey, is an ... 
Printer Friendly Version
01/15/10Celgene Completes Acquisition of Gloucester Pharmaceuticals
Transaction completed for $340 million in cash with additional milestone opportunities of up to $300 millionCommercial Launch of Novel HDAC Inhibitor, ISTODAX(R) (romidepsin), for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) Targeted For First Half of 2010SUMMIT, N.J., Jan 15, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced it has closed its acquisition of Gloucester Pharmaceuticals following the early termination of the applicable waiting period u... 
Printer Friendly Version
01/12/10Intergroupe Francophone du Myelome (IFM) Phase III Study (IFM 2005 02) Evaluating Treatment with Continuous REVLIMID(R) in Patients with Multiple Myeloma Following Autologous Stem Cell Transplant Meets Primary Endpoint
BOUDRY, Switzerland, Jan 12, 2010 (BUSINESS WIRE) -- Celgene International Sàrl (NASDAQ: CELG) today announced that the Intergroupe Francophone du Myelome and University Hospital of Toulouse, the sponsor of the study, reported that the independent Data and Safety Monitoring Committee, of the international Phase III, randomized, double-blind, multi-center clinical study (IFM 2005 02) evaluating REVLIMID(R) (lenalidomide) compared to placebo in multi... 
Printer Friendly Version
More >>
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Celgene Corp. posts new information to the site. Just enter your e-mail address and click Submit.
 
Copyright © 2008 MarketWatch, Inc. All rights reserved. Please see our Terms of Use.
Designed and powered by Dow Jones Client Solutions
Intraday data provided by Interactive Data Real Time Services and subject to the Terms of Use.
Intraday data is at least 20-minutes delayed. All times are ET.
Historical and current end-of-day data provided by Interactive Data Pricing and Reference Data.

Celgene Corporate Brochure

Featured Report
Science Writers' Guide
Nov. 10. 05
Science Writers' Guide (MDS)
Feb. 24. 06
Science Writers' Guide (MM)

IMiDs - Multiple Mechanisms - Acting in Concert 2006